05 October 2018 | News
Exemestane belongs to the group of medicines called aromatase inhibitor.
Zydus Cadila has received the final approval from the USFDA to market Exemestane Tablets, (US RLD – AROMASIN Tablets), 25 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.
The estimated sale for Exemestane Tablets is $68.6 million (Source: IMS Health, IMS National Sales Perspective Audit, MAT August 2018, extracted September 2018.)
Exemestane belongs to the group of medicines called aromatase inhibitor. It is used in women after menopause for the treatment of early breast cancer in women who have cancer that needs the female hormone estrogen to grow, have had other treatments for breast cancer for 2-3 years and are switching to Exemestane to complete 5 years in a row of hormonal therapy.
It is also used in the treatment of advanced breast cancer after treatment with other therapies, where it has not benefitted the patient or is no longer effective.
The group now has 220 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.